Grace Therapeutics, Inc. announced on September 22, 2025, that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 were presented at the 2025 Neurocritical Care Society annual meeting, held from September 18-21, 2025. The presentation, delivered by Dr. H. Alex Choi, highlighted the safety and tolerability of GTx-104 in the treatment of aneurysmal subarachnoid hemorrhage (aSAH). This public dissemination of data is crucial for medical community awareness.
The presented data reinforced the potential of intravenous GTx-104 to deliver neuroprotective effects while reducing hypotensive events compared to orally administered nimodipine. Additionally, subjects treated with GTx-104 showed improvements in ICU length of stay and a reduction in the need for mechanical ventilation. These findings provide a compelling case for GTx-104 as an alternative to oral nimodipine in hospital pharmacies, if approved by the FDA.
Grace Therapeutics' CEO, Prashant Kohli, noted that the presentation reinforced the potential of GTx-104 as a major innovation in aSAH treatment. Clinicians and pharmacists at the conference expressed excitement about GTx-104's potential to better manage hypotension and dose compliance. This positive reception from key medical professionals supports the product's market potential ahead of the April 23, 2026 PDUFA target date.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.